Glenmark Pharma Unveils generic anticoagulant injectable emulsion

Glenmark Pharmaceuticals announced that its US division has introduced the anticoagulant Phytonadione injectable emulsion. Glenmark Pharmaceuticals Inc., USA has introduced a 10 mg/mL injectable emulsion of Phytonadione in single-dose ampules, according to a company announcement.

The single-dose ampules are both bioequivalent and therapeutically equivalent to the reference drug, Vitamin K1 Injectable Emulsion USP, 10 mg/mL from Hospira, Inc., it further stated.

Commenting on the launch, Glenmark President & Business Head, North America Marc Kikuchi said, it grows the company's "portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients."

Referencing IQVIA data for the year ending November 2024, Glenmark reported that the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market reached annual sales of roughly USD 19.7 million in the United States.

Glenmark Pharmaceuticals was established in 1977 by Gracias Saldanha as a producer of generic medications and active pharmaceutical ingredients. He named the business in honor of his two sons. The business originally marketed its goods in India, Russia, and Africa. The firm became publicly traded in India in 1999 and allocated part of the funds to construct its initial research center.

On 29 January 2024, Glenmark Pharmaceuticals Ltd. and its subsidiary, Ichnos Sciences Inc., launched a partnership to create Ichnos Glenmark Innovation (IGI) focused on speeding up the advancement of novel cancer therapies.